KalVista Pharmaceuticals Management
Management criteria checks 2/4
KalVista Pharmaceuticals' CEO is Ben Palleiko, appointed in Mar 2024, has a tenure of less than a year. total yearly compensation is $6.77M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth $3.08M. The average tenure of the management team and the board of directors is 2.4 years and 3.7 years respectively.
Key information
Ben Palleiko
Chief executive officer
US$6.8m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | less than a year |
| CEO ownership | 0.6% |
| Management average tenure | 2.4yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
Sep 12
KalVista Pharmaceuticals: Looking To Be A Major Player In HAE
Sep 05Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
Jun 24KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Feb 14We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Jan 30We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Oct 04We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
May 02KalVista: Another Setback But The Key Value Driver Is Still In Place
Oct 14Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
Sep 24KalVista Pharmaceticals GAAP EPS of -$0.94
Sep 08KalVista reaches five-month high as rival tumbles on hereditary angioedema
Aug 22KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11
Jul 07Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
May 18Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth
Feb 02We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed
Sep 24We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely
Jul 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | -US$142m |
| Apr 30 2024 | US$7m | US$580k | -US$127m |
| Jan 31 2024 | n/a | n/a | -US$108m |
| Oct 31 2023 | n/a | n/a | -US$101m |
| Jul 31 2023 | n/a | n/a | -US$95m |
| Apr 30 2023 | US$2m | US$515k | -US$93m |
| Jan 31 2023 | n/a | n/a | -US$91m |
| Oct 31 2022 | n/a | n/a | -US$92m |
| Jul 31 2022 | n/a | n/a | -US$89m |
| Apr 30 2022 | US$3m | US$490k | -US$82m |
| Jan 31 2022 | n/a | n/a | -US$73m |
| Oct 31 2021 | n/a | n/a | -US$61m |
| Jul 31 2021 | n/a | n/a | -US$52m |
| Apr 30 2021 | US$1m | US$435k | -US$46m |
| Jan 31 2021 | n/a | n/a | -US$38m |
| Oct 31 2020 | n/a | n/a | -US$37m |
| Jul 31 2020 | n/a | n/a | -US$33m |
| Apr 30 2020 | US$1m | US$435k | -US$29m |
| Jan 31 2020 | n/a | n/a | -US$31m |
| Oct 31 2019 | n/a | n/a | -US$26m |
| Jul 31 2019 | n/a | n/a | -US$23m |
| Apr 30 2019 | US$2m | US$366k | -US$21m |
| Jan 31 2019 | n/a | n/a | -US$13m |
| Oct 31 2018 | n/a | n/a | -US$14m |
| Jul 31 2018 | n/a | n/a | -US$16m |
| Apr 30 2018 | US$821k | US$340k | -US$16m |
Compensation vs Market: Ben's total compensation ($USD6.77M) is above average for companies of similar size in the US market ($USD2.14M).
Compensation vs Earnings: Ben's compensation has increased whilst the company is unprofitable.
CEO
Ben Palleiko (58 yo)
less than a year
Tenure
US$6,772,197
Compensation
Mr. Benjamin L. Palleiko, also known as Ben, has been Director and Chief Executive Officer of KalVista Pharmaceuticals, Inc. from March 07, 2024. He served as President of KalVista Pharmaceuticals, Inc. fr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$6.77m | 0.62% $ 3.1m | |
| Chief Development Officer | 9yrs | US$1.37m | 0.21% $ 1.0m | |
| Chief Medical Officer | 3.5yrs | US$1.83m | 0.22% $ 1.1m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Vice President of Corporate Communications | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs & QA | no data | no data | no data | |
| Senior Vice President of Development | 5.5yrs | no data | no data | |
| Chief Commercial Officer | 1.3yrs | no data | no data | |
| Director of Finance and Company Secretary | no data | no data | no data |
2.4yrs
Average Tenure
51yo
Average Age
Experienced Management: KALV's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$6.77m | 0.62% $ 3.1m | |
| Independent Director | 9.9yrs | US$136.60k | 0% $ 0 | |
| Independent Chairman | 5.8yrs | US$161.60k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$136.60k | 0% $ 0 | |
| Independent Director | less than a year | US$143.78k | no data | |
| Board Observer | 9.3yrs | no data | no data | |
| Independent Director | 2.5yrs | US$124.10k | 0% $ 0 |
3.7yrs
Average Tenure
60yo
Average Age
Experienced Board: KALV's board of directors are considered experienced (3.7 years average tenure).